Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - methyl aminolevulinate hydrochloride, quantity: 200 mg/g (equivalent: methyl aminolevulinate, qty 160 mg/g) - cream - excipient ingredients: self-emulsifying glyceryl monostearate; cetostearyl alcohol; peg-40 stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; disodium edetate; glycerol; white soft paraffin; cholesterol; isopropyl myristate; arachis oil; almond oil; oleyl alcohol; purified water - treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp when other registered therapies are unacceptable. primary treatment of superficial and/or nodular basal cell carcinoma where surgery is considered inappropriate. treatment of biopsy-proven squamous cell carcinoma in situ (bowen's disease), where surgery is considered inappropriate. lumexia is indicated in adults above 18 years of age.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - methylene blue, quantity: 50 mg - injection - excipient ingredients: water for injections - proveblue is indicated: for the treatment of drug-induced methaemoglobinaemia. for the treatment of idiopathic methaemoglobinaemia (in which structural abnormality of haemoglobulin is not present). as a bacterial stain. as a dye in diagnostic procedures such as fistula detection. for the delineation of certain body tissues during surgery.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

affordable pharmaceuticals, llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution [see how supplied/storage and handling ( 16)] animal reproduction studies have not been conducted with peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution. it is also not known whether peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, modified release - excipient ingredients: brilliant blue fcf; croscarmellose sodium; methacrylic acid copolymer; polysorbate 80; purified talc; triethyl citrate; gelatin; colloidal anhydrous silica; simethicone; magnesium stearate; sodium lauryl sulfate; titanium dioxide; microcrystalline cellulose; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - tecfidera is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, modified release - excipient ingredients: colloidal anhydrous silica; gelatin; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; croscarmellose sodium; polysorbate 80; simethicone; methacrylic acid copolymer; magnesium stearate; brilliant blue fcf; microcrystalline cellulose; iron oxide yellow; triethyl citrate; sodium lauryl sulfate; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - tecfidera is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

galderma australia pty ltd - methyl aminolevulinate hydrochloride, quantity: 200 mg/g (equivalent: methyl aminolevulinate, qty 160 mg/g) - cream - excipient ingredients: self-emulsifying glyceryl monostearate; cetostearyl alcohol; peg-40 stearate; methyl hydroxybenzoate; propyl hydroxybenzoate; disodium edetate; glycerol; white soft paraffin; cholesterol; isopropyl myristate; arachis oil; almond oil; oleyl alcohol; purified water - treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp when other registered therapies are unacceptable. primary treatment of superficial and/or nodular basal cell carcinoma where surgery is considered inappropriate. treatment of biopsy-proven squamous cell carcinoma in situ (bowen's disease), where surgery is considered inappropriate. metvix is indicated in adults above 18 years of age.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - methyldopa (anhydrous) - oral tablet - 250mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - methyldopa (anhydrous) - oral tablet - 500mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - methyldopa (anhydrous) - oral tablet - 125mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

rebel distributors corp - methyldopa (unii: 56lh93261y) (methyldopa - unii:56lh93261y) - hypertension. methyldopa is contraindicated in patients: - with active hepatic disease, such as acute hepatitis and active cirrhosis. - with liver disorders previously associated with methyldopa therapy (see warnings ). - with hypersensitivity to any component of this product. - on therapy with monoamine oxidase (mao) inhibitors.